Use

The HLA-B*57:01 genotype test is significant for identifying individuals at increased risk of hypersensitivity reactions to abacavir based on the presence of the HLA-B*57:01 allele. The test is also useful for patients taking pazopanib who may have an increased risk of elevated alanine aminotransferase levels due to this allele. HLA-B*57:01 is associated with abacavir hypersensitivity reactions, which occur typically within the first six weeks of treatment and can be fatal. Identification of this allele aids in the prevention of starting abacavir in individuals who are at risk of hypersensitivity. Additionally, pazopanib-associated liver injury is linked to this allele carrier status.